ABSTRACT
The Antibody-based therapies offer the promise of meeting this need since antibodies play an important role in recognizing and eliminating invading microbial pathogens during the natural course of an infection. The several studies illustrate the importance of early administration of antibody therapy. The continual burden of disease caused by current and emerging respiratory viruses provides the impetus for research into novel therapeutic options. Much interest has been placed on antibody approaches due to their natural role in the immune response and their high target specificity. The many potently neutralizing monoclonal antibodies (mAbs) have been generated against clinically important respiratory viruses and an impressive amount of preclinical data exists for many of these mAbs. In this regard, the development of high-throughput methods to screen and characterize the diverse antibody repertoire would greatly facilitate and propel the selection and validation of antibody leads for combination antibody therapy.
